Gene Mutation Increases Risk of Neurodevelopmental Disorders
By LabMedica International staff writers Posted on 12 Sep 2017 |
Image: The gene variant, with a single amino acid switch from alanine to threonine in the brain-expressed G-protein coupled recepter CX3CR1, causes disruption of Akt signaling (Photo courtesy of Osaka University).
Researchers have found that a rare variant of the G protein-coupled receptor CX3CR1, due to only a single amino acid substitution, may become useful in predicting increased risk for developing schizophrenia and autism.
Huntington's disease, cystic fibrosis, and muscular dystrophy are diseases that can be traced to a single mutation. Diagnosis in asymptomatic patient for these diseases is relatively easy: you have the mutation? Then you are at risk. Complex diseases, on the other hand, do not have a clear mutational footprint. The new study, led by researchers at Nagoya University (Nagoya, Japan) and Osaka University (Osaka, Japan), have found a rare mutation that could act as a predictor for schizophrenia and autism.
"Aberrant synapse formation is important in the pathogenesis of schizophrenia and autism," said paper co-author Toshihide Yamashita, professor at Osaka University, "Microglia contribute to the structure and function of synapse connectivities." Microglia are the only cells in the brain that express the receptor CX3CR1. Mutations in this receptor are known to affect synapse connectivity and cause abnormal social behavior in mice. They have also been associated with neuroinflammatory diseases such as multiple sclerosis, but no study has shown a role in neurodevelopment disorders.
Working with this hypothesis, the researchers conducted a statistical analysis of the CX3CR1 gene in over 7000 schizophrenia and autism patients and healthy subjects, finding that one mutant candidate, a single amino acid switch from alanine to threonine, is a rare variant and a candidate marker for prediction. “Rare variants alter gene function but occur at low frequency in a population. They are of high interest for the study of complex diseases that have no clear mutational cause,” said Prof. Yamashita.
The structure of CX3CR1 includes a Helix-8 domain that is important for initiating a signaling cascade. Computer models showed that one amino acid change is enough to compromise the signaling. "The variant changes the region from hydrophobic to hydrophilic and destabilizes Helix 8. We overexpressed the mutation in cells and found Akt signaling was disrupted," explained Prof. Yamashita, adding that the findings are the first to connect a genetic variation in microglia with neurodevelopment disorders.
He hopes the discovery could become a basis for predictive diagnostics: "There is no reliable way to diagnose schizophrenia or autism in asymptomatic patients. Deeper understanding of the genetic risk factors will help us develop preventative measures," said Prof. Yamashita.
The study, by Ishizuka K et al, was published August 1, 2017, in the journal Translational Psychiatry.
Related Links:
Nagoya University
Osaka University
Huntington's disease, cystic fibrosis, and muscular dystrophy are diseases that can be traced to a single mutation. Diagnosis in asymptomatic patient for these diseases is relatively easy: you have the mutation? Then you are at risk. Complex diseases, on the other hand, do not have a clear mutational footprint. The new study, led by researchers at Nagoya University (Nagoya, Japan) and Osaka University (Osaka, Japan), have found a rare mutation that could act as a predictor for schizophrenia and autism.
"Aberrant synapse formation is important in the pathogenesis of schizophrenia and autism," said paper co-author Toshihide Yamashita, professor at Osaka University, "Microglia contribute to the structure and function of synapse connectivities." Microglia are the only cells in the brain that express the receptor CX3CR1. Mutations in this receptor are known to affect synapse connectivity and cause abnormal social behavior in mice. They have also been associated with neuroinflammatory diseases such as multiple sclerosis, but no study has shown a role in neurodevelopment disorders.
Working with this hypothesis, the researchers conducted a statistical analysis of the CX3CR1 gene in over 7000 schizophrenia and autism patients and healthy subjects, finding that one mutant candidate, a single amino acid switch from alanine to threonine, is a rare variant and a candidate marker for prediction. “Rare variants alter gene function but occur at low frequency in a population. They are of high interest for the study of complex diseases that have no clear mutational cause,” said Prof. Yamashita.
The structure of CX3CR1 includes a Helix-8 domain that is important for initiating a signaling cascade. Computer models showed that one amino acid change is enough to compromise the signaling. "The variant changes the region from hydrophobic to hydrophilic and destabilizes Helix 8. We overexpressed the mutation in cells and found Akt signaling was disrupted," explained Prof. Yamashita, adding that the findings are the first to connect a genetic variation in microglia with neurodevelopment disorders.
He hopes the discovery could become a basis for predictive diagnostics: "There is no reliable way to diagnose schizophrenia or autism in asymptomatic patients. Deeper understanding of the genetic risk factors will help us develop preventative measures," said Prof. Yamashita.
The study, by Ishizuka K et al, was published August 1, 2017, in the journal Translational Psychiatry.
Related Links:
Nagoya University
Osaka University
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders